Protagonist Therapeutics announced that the Company plans to begin clinical development of PN-10943, an oral, gut-restricted alpha-4-beta-7 integrin antagonist peptide for the treatment of inflammatory bowel disease, or IBD. In preclinical studies, PN-10943 has demonstrated superior properties to PTG-100 as measured by in vitro potency, target engagement based on in vivo pharmacodynamic, or PD, readouts of blood receptor occupancy and effects on T cell trafficking, and efficacy in disease models of colitis. The Company is replacing PTG-100 with PN-10943 as a development candidate for the treatment of IBD based on an assessment of preclinical data from PN-10943 and recent feedback from global regulatory authorities on further development of PTG-100.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.